

## SYNTHESIS AND ANTIVIRAL ACTIVITY OF MODIFIED 5 $\alpha$ -STEROIDS

N. Sh. Nadaraia,\* N. N. Barbakadze, M. L. Kakhbrishvili,  
K. G. Mulkidzhanyan, and M. Z. Getia

Hydrazones are a class of organic compounds possessing various biological activities [1, 2].


Steroid oximes, thiosemicarbazones, semicarbazones, and hydrazones have attracted interest because of their high pharmacological activity, e.g., antibacterial, antiviral, antitumor, etc. [3–6].

Transformation into ester derivatives is a common method of structural modification of steroids. Addition of an ester into the steroid core affects the biological activity. The cytotoxicity of several steroid esters synthesized via esterification of a hydroxyl group was shown to be significantly less than that of their precursors [7].

Previously, we reported that several epandrosterone hydrazones modified by phenylacetic acid chloride exhibited antiviral activity [8].

In continuation of research on the synthesis of new biologically active steroids, several new (**2–7**) and previously known hydrazones (**8** and **9**) [9, 10] were prepared from 5 $\alpha$ -pregnenolone acetate **1** and tested for antiviral activity. Compound **2** was synthesized from steroid **1**; hydrazones **3–6**, from ketone **10** via reaction with hydrazides or hydrazines (hydrazides of *m*-nitrobenzoic, *m*-bromobenzoic, and salicylic acids and 2,4-dinitrophenyl- and *p*-nitrophenylhydrazine) in EtOH in the presence of a catalytic amount of AcOH. Oxime **7** was obtained from 3 $\beta$ -(1-adamantoate)-5 $\alpha$ -androstan-17-one; this ketone and starting **10**, via esterification of epandrosterone **11** by the literature method [8].

The structures of the synthesized steroids **2–7** were confirmed using IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, and mass spectra. IR spectra of **2**, **3**, **6**, and **7** contained absorption bands for ester C=O in the range 1750–1668 cm<sup>-1</sup>; for NHCO (hydrazones **2** and **3**), at 1667 and 1665 cm<sup>-1</sup>; for stretching vibrations of C=N and aromatic C=C double bonds (steroids **2**, **3**, and **6**), at 1640–1602 and 1562–1560 cm<sup>-1</sup>, respectively; for hydrazone NH of **6** and OH and C=N of oxime **7**, at 3373, 3278, and 1658 cm<sup>-1</sup>, respectively. IR spectra of nitro derivatives **2** and **6** also had characteristic Ar–NO<sub>2</sub> stretching vibrations at 1500 and 1506 and 1374 and 1375 cm<sup>-1</sup>, respectively.



I. Kutateladze Institute of Pharmacochemistry, Tbilisi State Medical University, 0159, Tbilisi, Georgia, fax: (99532) 52 00 23, e-mail: n.nadaraia@tsmu.edu. Translated from *Khimiya Prirodnikh Soedinenii*, No. 1, January–February, 2022, pp. 153–155. Original article submitted July 6, 2021.

The  $^1\text{H}$  NMR spectra of **2–7** exhibited singlets for  $\text{CH}_3$ -18 and  $\text{CH}_3$ -19 methyls at  $\delta$  0.95–0.85 and 1.05–0.89 ppm, respectively. The aromatic protons of **2–6** had chemical shifts (CSs) in the range 9.11–6.85 ppm. Singlets for the methylene protons of the phenylacetoxy groups of hydrazones **3–6** were observed at  $\delta$  3.51; the resonances of NH groups of steroids **5** and **6**, at 10.76 and 9.30; the NHCO protons of **2–4**, in the range  $\delta$  9.00–8.35 ppm. Multiplets of the  $3\alpha$  protons from the  $3\beta$  esters of steroids **2–7** showed CSs at  $\delta$  4.65–4.59 ppm. A broad singlet from the  $\text{C}=\text{N}-\text{OH}$  proton of oxime **7** appeared at  $\delta$  7.43 ppm. Resonances of other protons agreed with the proposed structures.  $^{13}\text{C}$  NMR spectra of hydrazones **4** and **5** had C-3 resonances at  $\delta$  74.0 ppm; aromatic C atoms, in the range  $\delta$  154.9–116.4; of  $\text{C}=\text{N}$  bonds,  $\delta$  171.2–161.9; of  $\text{O}-\text{C}=\text{O}$  groups, at  $\delta$  171.2 and 172.3 ppm, respectively. The resonance of the  $\text{NH}-\text{CO}$  C atom of **4** had a CS of  $\delta$  158.8 ppm.

Mass spectra confirmed the empirical formulas of **2–7**.

Screening for specific antiviral activity of **6** was performed by the National Institute of Allergy and Infectious Diseases at the University of Utah (USA) using the following virus strains: *Polio virus* (Vero 76 cell culture, strain Type 3, WM-3); *SARS-corona virus* (Vero 76 cell culture, strain Urbani); *Rift Valley fever virus* (Vero 76 cell culture, strain MP-12); *Tacaribe virus* (Vero cell culture, strain TRVL-11573); *Venezuelan equine encephalitis virus*, *Respiratory syncytial virus*, *Influenza A virus*  $\text{H}_1\text{N}_1$ , *Dengue virus* (Vero cell culture, MA-104, MDCK; Vero 76; strains TC-83, A-2, California 07/2009, Type 2, New Guinea C, respectively); and *Cytomegalovirus* (strains Davis and AD-169) and *varicella-zoster virus* (strains OKA and 07-1); of compounds **2–5** and **7–9**, at Rega Institute for Medical Research, Belgium. As it turned out, only hydrazone **6** exhibited moderate antiviral activity against *Polio virus*. All other compounds did not possess any significant activity against these strains.

Steroids **2–6** and **8** were prepared by the literature method [11]; oxime **7**, as before [8]; androst-4-en-3,17-dione bis-thiosemicarbazone **9**, by the literature method [10].

**3 $\beta$ -Acetoxy-5 $\alpha$ -pregn-16-en-20-one *m*-Nitrobenzoylhydrazone (2).** Yield 72%, mp 186–188°C. IR (KBr, v,  $\text{cm}^{-1}$ ): 3425 (NH), 1750 (C=O), 1667 (NH-CO), 1640 (C=N), 1561 (arom. ring), 1500 and 1374 (Ar- $\text{NO}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.89 (3H, s,  $\text{CH}_3$ -18), 1.05 (3H, s,  $\text{CH}_3$ -19), 1.96 (3H, s,  $\text{CH}_3$ -21), 2.07 (3H, s,  $\text{OCOCH}_3$ ), 4.59 (1H, m, H-3), 6.19 (1H, s, H-16), 7.61 (1H, t,  $J = 8.2$ , H-5'), 8.10 (1H, d,  $J = 7.1$ , H-6'), 8.35 (1H, d,  $J = 7.3$ , H-4'), 8.64 (1H, s, H-2'), 9.00 (1H, br.s, NHCO). LC-MS,  $m/z$  522 [M + H] $^+$ .  $\text{C}_{30}\text{H}_{39}\text{N}_3\text{O}_5$ . MW 521.

**3 $\beta$ -Phenylacetoxy-5 $\alpha$ -androstan-17-one *m*-Bromobenzoylhydrazone (3).** Yield 81%, mp 159–161°C. IR (KBr, v,  $\text{cm}^{-1}$ ): 3412 (NH), 1729 (C=O), 1665 (NH-CO), 1602 (C=N), 1562 (arom. ring).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.85 (3H, s,  $\text{CH}_3$ -18), 0.95 (3H, s,  $\text{CH}_3$ -19), 2.18–2.25 (2H, m, H-16), 3.51 (2H, s,  $\text{CH}_2\text{C}_6\text{H}_5$ ), 4.61 (1H, m, H-3), 7.24–7.34 (5H, m,  $\text{C}_6\text{H}_5$ ), 7.52–8.25 (4H, ArH), 8.35 (1H, br.s, NHCO). LC-MS,  $m/z$  606 [M + H] $^+$ .  $\text{C}_{34}\text{H}_{41}\text{BrN}_2\text{O}_3$ . MW 605.

**3 $\beta$ -Phenylacetoxy-5 $\alpha$ -androstan-17-one Salicyloylhydrazone (4).** Yield 67%, mp 254–256°C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.95 (3H, s,  $\text{CH}_3$ -18), 0.98 (3H, s,  $\text{CH}_3$ -19), 2.40–2.51 (2H, m, H-16), 3.51 (2H, s,  $\text{CH}_2\text{C}_6\text{H}_5$ ), 4.61 (1H, m, H-3), 6.85–7.41 (9H, ArH), 8.65 (1H, br.s, NH-CO).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm): 12.2, 16.9, 20.7, 23.4, 25.2, 27.4, 28.3, 31.4, 33.8, 33.9, 34.9, 35.7, 36.7, 41.8, 44.6, 45.3, 53.3, 54.4, 74.0 (C-3), 117.2 (C-1''), 117.6 (C-3''), 118.6 (C-5''), 125.0 (C-6''), 126.9 (C-4'), 128.5 (C-3', 5'), 129.2 (C-2', 6'), 134.3 (C-4''), 134.5 (C-1'), 154.9 (C-2''), 158.8 (NHCO), 161.9 (C=N), 171.2 (O=C=O). LC-MS,  $m/z$  543 [M + H] $^+$ .  $\text{C}_{34}\text{H}_{42}\text{N}_2\text{O}_4$ . MW 542.

**3 $\beta$ -Phenylacetoxy-5 $\alpha$ -androstan-17-one 2,4-Dinitrophenylhydrazone (5).** Yield 76%, mp 198–200°C.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.87 (3H, s,  $\text{CH}_3$ -18), 0.95 (3H, s,  $\text{CH}_3$ -19), 2.50–2.65 (2H, m, H-16), 3.51 (2H, s,  $\text{CH}_2\text{C}_6\text{H}_5$ ), 4.61 (1H, m, H-3), 7.26–7.34 (5H, m,  $\text{C}_6\text{H}_5$ ), 7.93 (1H, d,  $J = 9.5$ , ArH), 8.28 (1H, dd,  $J = 9.5, 2.5$ , ArH), 9.11 (1H, d,  $J = 2.5$ , ArH), 10.76 (1H, s, NH).  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm): 12.3, 17.2, 20.7, 23.5, 26.4, 27.4, 28.3, 31.4, 33.9, 34.1, 35.0, 35.7, 36.7, 41.8, 44.7, 45.3, 53.5, 54.4, 74.0 (C-3), 116.4 (C-6''), 123.6 (C-3''), 126.9 (C-4'), 128.5 (C-3', 5'), 128.8 (C-2''), 129.2 (C-2', 6'), 129.9 (C-5''), 134.3 (C-1'), 137.5 (C-4''), 145.4 (C-1''), 171.2 (C=N), 172.3 (O=C=O). LC-MS,  $m/z$  589 [M + H] $^+$ .  $\text{C}_{33}\text{H}_{40}\text{N}_4\text{O}_6$ . MW 588.

**3 $\beta$ -Phenylacetoxy-5 $\alpha$ -androstan-17-one *p*-Nitrophenylhydrazone (6).** Yield 83%, mp 221–223°C. IR (KBr, v,  $\text{cm}^{-1}$ ): 3373 (NH), 1668 (C=O), 1615 (C=N), 1560 (arom. ring), 1506 and 1375 (Ar- $\text{NO}_2$ ).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.85 (3H, s,  $\text{CH}_3$ -18), 0.89 (3H, s,  $\text{CH}_3$ -19), 2.38–2.50 (2H, m, H-16), 3.51 (2H, s,  $\text{CH}_2\text{C}_6\text{H}_5$ ), 4.61 (1H, m, H-3), 7.10 (2H, d,  $J = 9.0$ , ArH), 7.18–7.28 (5H, m,  $\text{C}_6\text{H}_5$ ), 8.00 (2H, d,  $J = 9.1$ , ArH), 9.30 (1H, s, NH), LC-MS,  $m/z$  544 [M + H] $^+$ .  $\text{C}_{33}\text{H}_{41}\text{N}_3\text{O}_4$ . MW 543.

**17-Hydroximino-3 $\beta$ -(1-adamantoate)-5 $\alpha$ -androstane (7).** Yield 87%, mp 245–247°C. IR (KBr, v,  $\text{cm}^{-1}$ ): 3278 (OH), 2924, 2851 (CH-Ad), 1731 (C=O), 1658 (C=N).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 0.87 (3H, s,  $\text{CH}_3$ -18), 0.89 (3H, s,  $\text{CH}_3$ -19), 1.74 (3H, s, CH-Ad), 1.88 (10H, s,  $\text{CH}_2$ -Ad), 1.99 (2H, s,  $\text{CH}_2$ -Ad), 2.40–2.55 (2H, m, H-16), 4.65 (1H, m, H-3), 7.43 (1H, br.s, C=N-OH). LC-MS,  $m/z$  468 [M + H] $^+$ .  $\text{C}_{30}\text{H}_{45}\text{NO}_3$ . MW 467.

## REFERENCES

1. S. Chen, J. Cui, Y. Li, and L. Fan, *Chin. J. Org. Chem.*, **31** (2), 187 (2011).
2. G. Verma, A. Marella, M. Shaquiquzzaman, M. Akhtar, M. R. Ali, and M. M. Alam, *J. Pharm. Bioallied Sci.*, **6** (2), 69 (2014).
3. Ch. Gan, J. Cui, Sh. Su, Q. Lin, L. Jia, L. Fan, and Y. Huang, *Steroids*, **87**, 99 (2014).
4. S. A. Khan, P. Kumar, R. Joshi, P. F. Iqbal, and K. Saleem, *Eur. J. Med. Chem.*, **43**, 2029 (2008).
5. M. Alam and D. U. Lee, *Korean J. Chem. Eng.*, **32** (6), 1142 (2015).
6. Ch. Gan, L. Liu, J. Cui, Zh. Liu, H. Shi, Q. Lin, H. Sheng, Ch. Yang, and Y. Huang, *Med. Chem.*, **13**, 375 (2017).
7. Y. Huang, H. Wen, J. Zheng, Ch. Gan, L. Pang, Ch. Pang, X. Liu, J. Zhan, and J. Cui, *Nat. Prod. Res.*, 1 (2018).
8. N. Sh. Nadaraia, N. N. Barbakadze, M. L. Kakhbrishvili, B. Sylla, A. Pichette, and U. S. Makhmudov, *Chem. Nat. Compd.*, **54**, 310 (2018).
9. N. Sh. Nadaraia, N. N. Barbakadze, M. L. Kakhbrishvili, and V. D. Mshvildadze, *Res. J. Pharm., Biol. Chem. Sci.*, **10** (1), 239 (2019).
10. M. B. Zivkovic, I. Z. Matic, M. V. Rodic, I. T. Novakovic, D. M. Sladic, and N. M. Krstic, *RSC Adv.*, **6** (41), 34312 (2016).
11. N. Sh. Nadaraia, M. L. Kakhbrishvili, N. N. Barbakadze, V. D. Mshvildadze, K. G. Mulkidzhanyan, and A. Pichette, *Chem. Nat. Compd.*, **57**, 395 (2021).